Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant staphylococcus aureus: A multicenter clinical trial

Clinical Infectious Diseases

Volumn 59, Issue 8, 2014, Pages 1105-1112

  Del Río, Ana ^a   Gasch, Oriol ^a,b   Moreno, Asunción ^a   Peña, Carmen ^a   Cuquet, Jordi ^c,f   Soy, Dolors ^a   Mestres, Carlos A ^a   Suárez, Cristina ^a   Pare, Juan C ^a   Tubau, Fe ^a,d   De La Mària, Cristina Garcia ^a   Marco, Francesc ^a,e   Carratalà, Jordi ^a   Gatell, José M ^a   Gudiol, Francisco ^a,f   Miró, José M ^a   Pericas, Juan M ^a   Cervera, Carlos ^a   Armero, Yolanda ^a   Almela, Manel ^a   Fuster, David ^a   Cartañá, Ramón ^a   Ninot, Salvador ^a   Azqueta, Manel ^a   Sitges, Marta ^a   Heras, Magda ^a   Pomar, José L ^a   Ramírez, Jose ^a   Brunet, Mercè ^a   Llopis, Jaume ^a   Pujol, Miquel ^a   Ariza, Javier ^a   Martí, Carmina ^f   Mijana, Mireia ^f   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL GENERAL DE GRANOLLERS   (Spain)

Author keywords

Bacteremia; Fosfomycin; Imipenem; Infective endocarditis; MRSA

Indexed keywords

DAPTOMYCIN; FOSFOMYCIN; IMIPENEM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; BLOOD VESSEL GRAFT; BLOODSTREAM INFECTION; CAUSE OF DEATH; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT INFECTION; HUMAN; HYPERNATREMIA; LEUKOPENIA; LIVER CIRRHOSIS; MALE; METABOLIC ACIDOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE ORGAN FAILURE; PARACENTESIS; PRIORITY JOURNAL; TREATMENT OUTCOME; ADVERSE EFFECTS; BACTEREMIA; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDOCARDITIS, BACTERIAL; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; SALVAGE THERAPY; SPAIN; STAPHYLOCOCCAL INFECTIONS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BLOOD; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDOCARDITIS, BACTERIAL; FEMALE; FOSFOMYCIN; HUMANS; IMIPENEM; INFUSIONS, INTRAVENOUS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; SALVAGE THERAPY; SPAIN; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84930160796     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu580     Document Type: Article

References (39)

1. European Centre for Disease Prevention and Control. Annual Epidemiological Report on Communicable Diseases in Europe 2010. Stockholm: ECDC, 2010. Available at: http://www.rivm.nl/earss/. 2011. Accessed 24 September 2013.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H,Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
3. Miro JM, Anguera I, Cabell CH, et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2005; 41:507-14.
4. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-55.
5. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227-31.
6. Jefferson KK, Goldmann DA, Pier GB. Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms. Antimicrob Agents Chemother 2005; 49:2467-73.
7. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006; 42(suppl 1):S51-7.
8. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992; 36:2709-14.
9. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 2009; 9:617-24.
10. Fowler VG Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
11. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 1974; 235:364-86.
12. Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 2010; 29:127-42.
13. Drugeon HB, Courtieu AL. The role of culture media on the fosfomycin sensitivity of six Serratia strains and their resistant mutants. Chemotherapy 1982; 28:345-50.
14. Duez JM, Kohli E, Pechinot A, Tremeaux JC, Kazmierczak A. Combination between fosfomycin and oxacillin or cefotaxime against methicillin-resistant staphylococci and enterococci. Pathol Biol (Paris) 1983; 31:515-8.
15. Fosse T, David MF, Duluc F, Darmusey D, Tamalet C, Toga B. In vitro study of the cefamandole-fosfomycin combination against methicillinresistant staphylococci. Pathol Biol (Paris) 1984; 32(5 Pt 2):528-31.
16. Alvarez S, Jones M, Berk SL. In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985; 28:689-90.
17. Kazmierczak A, Pechinot A, Tremeaux JC, Duez JM, Kohli E, Portier H. Bactericidal activity of cefotaxime and fosfomycin in cerebrospinal fluid during the treatment of rabbit meningitis experimentally induced by methicillin-resistant Staphylococcus aureus. Infection 1985; 13(suppl 1): S76-80.
18. Matsuda K, Asahi Y, Sanada M, Nakagawa S, Tanaka N, Inoue M. Invitro activity of imipenem combined with beta-lactam antibiotics for methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1991; 27:809-15.
19. Utsui Y, Ohya S, Magaribuchi T, Tajima M, Yokota T. Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin-And cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1986; 30:917-22.
20. Nakazawa H, Kikuchi Y, Honda T, Isago T, Nozaki M. Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin. J Infect Chemother 2003; 9:304-9.
21. Debbia E, Varaldo PE, Schito GC. In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin. Antimicrob Agents Chemother 1986; 30:813-5.
22. Marco F, Miró JM, del Rio A, et al. Efficacy of fosfomycin (Fos) plus imipenem( Imi) or ceftriaxone (Cro) combinations in the treatment of experimental endocarditis (EE) due to methicillin-resistant Staphylococcus aureus (MRSA). [abstract 1009]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Toronto (Canada): American Society for Microbiology, 2000.
23. Fukuda K, Yoshio K, Handa S, Yoshikawa T, Uchida H, Nakamura Y. A successful treatment of an infective endocarditis caused by methicillinresistant Staphylococcus aureus with a combination of cefmetazole with fosfomycin. Jpn J Antibiot 1989; 42:1913-8.
24. Portier H, Tremeaux JC, Chavanet P, Gouyon JB, Duez JM, Kazmierczak A. Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combination. J Antimicrob Chemother 1984; 14(suppl B): 277-84.
25. Portier H, Kazmierczak A, Lucht F, Tremeaux JC, Chavanet P, Duez JM. Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infection 1985; 13 (suppl 1):S123-8.
26. Kono K, Takeda S, Tatara I, et al. Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections. Jpn J Antibiot 1994; 47:798-803.
27. Miro JM, Entenza JM, Del RA, et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2012; 56:4511-5.
28. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30:633-8.
29. FitzGerald SF, Kelly C, Humphreys H. Diagnosis and treatment of prosthetic aortic graft infections: confusion and inconsistency in the absence of evidence or consensus. J Antimicrob Chemother 2005; 56:996-9.
30. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-40.
31. Friedman ND, Kaye KS, Stout JE, et al. Health care-Associated bloodstream infections in adults: a reason to change the accepted definition of community-Acquired infections. Ann Intern Med 2002; 137:791-7.
32. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S21. Wayne, PA, USA: CLSI, 2011.
33. Fowler VG Jr., Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012-21.
34. Tattevin P, Uhel F, Fily F. Observational studies of salvage treatment for persistent bacteremia: beware of survivor treatment selection bias. Clin Infect Dis 2009; 49:1960.
35. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal betalactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53:158-63.
36. Lopez J, Sevilla T, Vilacosta I, et al. Prognostic role of persistent positive blood cultures after initiation of antibiotic therapy in left-sided infective endocarditis. Eur Heart J 2013; 34:1749-54.
37. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674-80.
38. Florent A, Chichmanian RM, Cua E, Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents 2011; 37:82-3.
39. Rodriguez A, Gallego A, Olay T, Mata JM. Bacteriological evaluation of fosfomycin in clinical studies. Chemotherapy 1977; 23(suppl 1):247-58.